Spadin‑derived PE 22‑28: Fast‑acting antidepressant or hype?

Posted by amber464 in Research & News - 1 points, 0 comments.

I just read a 2024 preclinical paper on the spadin‑derived peptide PE 22‑28 (https://researchsafe.io/peptides/pe-22-28). The authors injected the peptide into mice and ran a forced‑swim test. Within hours the depressed‑like behavior dropped to levels similar to fluoxetine, but the mice looked calmer and had more spontaneous activity. The paper claims that blocking TREK‑1 channels ramps up serotonergic signaling and triggers rapid synaptogenesis. For me, that sounds promising, especially since I’ve tried a handful of nootropics for mood with mixed results. The idea that a single peptide could give an antidepressant effect in a few hours is pretty wild, and a lower risk of the long‑term side effects seen with SSRIs would be a boon.

Still, it’s only a mouse study. The half‑life is short, and I don’t see any proof that it would cross the human blood‑brain barrier or that the dose would be safe. I’m skeptical but not dismissing it outright. Anyone here been tracking TREK‑1 blockers or ড strategies? What’s your take on moving from animal data to human trials?

Community discussion - research and educational context only. Not medical advice.